Current Drug Treatment News and Events | Page 2

Current Drug Treatment News and Events, Drug Treatment News Articles.
Sort By: Most Relevant | Most Viewed
Page 2 of 25 | 1000 Results
Calibrating kidney function for cancer patients
A new model to evaluate kidney function can help clinicians find the right balance between treating cancer and avoiding chemotherapy's dangerous side effects. (2020-12-10)

NUS researchers finds best combination of available therapies against COVID-19
Researchers from the National University of Singapore have utilised a ground-breaking AI platform to find an optimal combination of available therapies against COVID-19. The research team identified the drug combination from over 530,000 possibilities within two weeks, cutting down the number of tests typically needed by hundreds of thousands. (2020-12-10)

Using targeted microbubbles to administer toxic cancer drugs
New research has shown how microbubbles carrying powerful cancer drugs can be guided to the site of a tumour using antibodies. Microbubbles are small manufactured spheres half the size of a red blood cell - and scientists believe they can be used to transport drugs to highly specific locations within the body. (2020-12-08)

Potential cancer therapy may boost immune response
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug gemcitabine into a drug that kills cancer cells in a specialized way, activating immune cells to fight the cancer, according to a study led by Cedars-Sinai Cancer investigators. (2020-12-07)

A library of mice to look up the best liver cancer treatment
Researchers from Osaka University have developed a mouse model that reproduces the real-world variety of genetic drivers of liver cancer, and used this model to discover that tumors driven by the gene FGF19 are especially vulnerable to treatment with the drug lenvatinib. They also found a serum biomarker that may help indicate which patients have this specific type of cancer, potentially leading to improved treatment selection and outcomes. (2020-12-07)

Drug for rare disorder shows promise for treating herpes viruses
New research shows that the antiviral activity of the drug -- called phenylbutyrate, or PBA -- was even better when used along with acyclovir, a common HSV-1 treatment. When used in combination, less acyclovir is needed to effectively suppress the virus compared to acyclovir alone -- this is important because acyclovir is also known to have toxic side effects in the kidneys. (2020-12-07)

Secukinumab in children with plaque psoriasis: Study unsuitable for benefit assessment
Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment The comparator group was not treated appropriately. Firstly, therapy in this group remained unchanged despite non-response, and secondly, it was continued for longer than approved. (2020-12-04)

Oral drug blocks SARS-CoV-2 transmission, Georgia State biomedical sciences researchers find
Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered. (2020-12-03)

Warning signs over effectiveness of HIV 'wonder drug' in sub-Saharan Africa
Dolutegravir, the current first-line treatment for HIV, may not be as effective as hoped in sub-Saharan Africa, suggests new research published on World AIDS Day. The study finds that this so-called 'wonder drug' may be less effective in patients resistant to older drugs. (2020-12-01)

AI predicts which drug combinations kill cancer cells
A machine learning model developed in Finland can help us treat cancer more effectively. (2020-12-01)

COVID-19: Fall in cancer drug treatment rose quickly following 'rapid' NHS guidance
The number of patients starting anticancer therapies dropped by more than 30 per cent in April, the month following the UK's first COVID-19 lockdown, but went above pre-pandemic levels within three months, finds a new study of NHS England data co-led by UCL researchers. (2020-11-27)

New breakthrough in the treatment of rheumatoid arthritis
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment, otilimab, that not only suppresses inflammation but also significantly reduces patient reported pain scores. (2020-11-25)

Experimental evolution reveals how bacteria gain drug resistance
A research team at RIKEN in Japan has succeeded in experimentally evolving the common bacteria under pressure from a large number of individual antibiotics, and identified the mechanisms and constraints underlying evolved drug resistance. Their findings help develop drug-treatment strategies that minimize the chance that bacteria will develop resistance. (2020-11-24)

Adverse childhood experiences and at-risk drinking, cannabis, and illicit drug use
New research from the Prevention Research Center of the Pacific Institute for Research and Evaluation suggests that adverse childhood experiences, often referred to as child maltreatment, are associated with increased odds of substance use among women urban Emergency Department patients. (2020-11-22)

Drug eases recovery for those with severe alcohol withdrawal
Yale scientists say a drug originally developed to treat high blood pressure can reduce severe withdrawal symptoms for patients diagnosed with alcohol use disorder. (2020-11-19)

Potential new target to combat inflammatory diseases
An international team of researchers have uncovered a drug-like compound that blocks a crucial inflammatory pathway, potentially paving the way for a new treatment for a host of diseases - including COVID-19. WEHI's Associate Professor Seth Masters and his research team discovered the compound could prevent up-regulation of CD14, a key inflammatory protein. The discovery was recently published in EBioMedicine. (2020-11-19)

UTSA researcher examines drug overdose mortality in the Hispanic community
UTSA researcher Manuel Cano, assistant professor in the Department of Social Work at UTSA is shedding light to understand the topic of drug overdose deaths in the Hispanic community. In the article ''Drug Overdose Deaths Among US Hispanics: Trends (2000-2017) and Recent Patterns'' published in ''Substance Use & Misuse'' Cano used national death certificate data (data recording all deaths of U.S. residents) to examine drug overdose mortality in different Hispanic subgroups, based on heritage, place of birth and gender. (2020-11-18)

Trifarotene in moderate acne: No study data for the assessment of the added benefit
Trifarotene in moderate acne: no study data for the assessment of the added benefit. Although acne affects many people and there are treatment alternatives, the new drug was only compared with placebo in the approval studies. (2020-11-16)

Approved JAK inhibitor baricitinib shows promise against cytokine storm in COVID-19 clinical study
A clinical study involving 601 patients in Italy and Spain suggests that the JAK inhibitor drug baricitinib may enhance survival rates of patients (2020-11-13)

New cancer drugs saved over 1.2 million people in the US over 16 years, new study shows
More than 1.2 million people in the US prevented facing death following a cancer diagnosis, between the year 2000 and 2016, thanks to ever improving treatment options -- a large new national study shows. (2020-11-09)

Therapeutic drug monitoring does not improve remission for patients starting infliximab
New research presented at ACR Convergence, the American College Rheumatology's annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care. (2020-11-06)

Large-scale cancer proteomics study profiles protein changes in response to drug treatments
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas MD Anderson Cancer Center have generated a valuable resource to aid in predicting drug sensitivity, to understand therapeutic resistance mechanisms and to identify optimal combination treatment strategies. (2020-11-05)

Precision chemo-immunotherapy for pancreatic cancer?
Pancreatic cancer is highly lethal: according to the National Cancer Institute, only about 10 percent of patients remain alive five years after diagnosis. Now, a preclinical study from the lab of Marsha Moses, PhD at Boston Children's Hospital, reports marked and lasting tumor regression in a mouse model, using a highly selective, potent, engineered antibody-drug combination. (2020-11-05)

Machine learning that predicts anti-cancer drug efficacy
Research on anti-cancer drug response in patient-derived artificial organoids and transcriptome learning of genes associated with anti-cancer target proteins. (2020-11-01)

Giving the immune system a double boost against cancer
Cancer immunotherapies are very effective for some patients, but many cancers do not respond to the currently available treatments. Researchers are developing a new approach that expands the number of treatable tumor types. (2020-10-30)

Stronger treatments could cure Chagas disease
Researchers in the University of Georgia's Center for Tropical and Emerging Global Diseases have found that a more intensive, less frequent drug regimen with currently available therapeutics could cure the infection that causes Chagas disease (2020-10-29)

Exposure to suboptimal doses of antimalarial drugs could, under certain circumstances, increase mala
Exposure to suboptimal doses of the antiparasitic drug artemisinin could increase the sexual conversion rate of the malaria parasite Plasmodium falciparum, thereby increasing the probability of transmission, according to a study led by the Barcelona Institute for Global Health (ISGlobal), an institution supported by ''la Caixa'' Foundation. The findings, published in eLife, may have public health implications, particularly in the context of mass antimalarial drug administration campaigns. (2020-10-28)

Computer vision helps find binding sites in drug targets
Scientists from the iMolecule group at Skoltech developed BiteNet, a machine learning (ML) algorithm that helps find drug binding sites, i.e. potential drug targets, in proteins. BiteNet can analyze 1,000 protein structures in 1.5 minutes and find optimal spots for drug molecules to attach. (2020-10-27)

Next generation BRAF inhibitor cancer drug shows promise in early patient trial
A new drug designed to work on cancers with an altered BRAF gene has shown promise in an early patient trial presented at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online. (2020-10-25)

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications. (2020-10-22)

New drug that can prevent the drug resistance and adverse effects
A research team in Korea is garnering attention for having developed an anticancer drug that could potentially prevent drug resistance. The Korea Institute of Science and Technology (KIST) announced that a team of researchers led by Dr. Kwang-meyung Kim at the Theragnosis research center successfully developed a cancer-specific anticancer drug precursor that can prevent the drug resistance. (2020-10-21)

New dimensions in the treatment of muscle spasticity after stroke and nervous system defects
Chronic muscle spasticity after nervous system defects like stroke, traumatic brain and spinal cord injury, multiple sclerosis and painful low back pain affect more than 10% of the population, with a socioeconomic cost of about 500 billion USD. Currently, there is no satisfying remedy to help these suffering people, which generates an immense medical need for a new generation antispastic drug. Drug candidate MPH-220 could mean new hope for millions of patients suffering from spasticity. (2020-10-16)

Drug repurposing
University of New Mexico researchers identify three existing drugs with the potential to clear SARS-CoV-2 infections. (2020-10-16)

Study reveals most effective drugs for common type of neuropathic pain
More than 20 million people in the U.S. suffer neuropathic pain. At least 25% of those cases are classified as unexplained and considered cryptogenic sensory polyneuropathy (CSPN). There is no information to guide a physician's drug choices to treat CSPN, but a researcher from the University of Missouri School of Medicine and MU Health Care led a first-of-its-kind prospective comparative effectiveness study. (2020-10-15)

Penn Medicine researchers use artificial intelligence to 'redefine' Alzheimer's Disease
The researchers will apply advanced artificial intelligence (AI) methods to integrate and find patterns in genetic, imaging, and clinical data from over 60,000 Alzheimer's patients -- representing one of the largest and most ambitious research undertakings of its kind. (2020-10-14)

More evidence of benefits of REGN-COV2 antibody cocktail to both protect from and treat disease
In June, two studies in Science reported an antibody cocktail against SARS-CoV-2 developed from studies in humanized mice and recovering patients. (2020-10-09)

Hydroxychloroquine does not counter SARS-CoV-2 in hamsters, high dose of favipiravir does
Virologists from the KU Leuven Rega Institute in Belgium have shown that a treatment with the anti-malaria drug hydroxychloroquine does not limit SARS-CoV-2 coronavirus replication in hamsters. A high dose of the anti-flu drug favipiravir, by contrast, has an antiviral effect in the hamsters. The team published their findings in the Proceedings of the National Academy of Sciences (PNAS). (2020-10-09)

Suicide deaths among youth following antidepressant boxed warnings
A public health advisory issued by the US Food and Drug Administration (FDA) in 2003, followed by drug label warnings, indicated that children and adolescents taking antidepressants were at increased risk of developing suicidal thoughts and behaviors. Research has shown that these warnings reduced the diagnosis and treatment of depression among young people. Now, a new study suggests that the warnings may also have contributed to an increase in suicide deaths among youth. (2020-10-07)

Advanced prostate cancer has an unexpected weakness that can be targeted by drugs
Kanazawa University researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer. RB1 deletion makes cells resistant to hormone therapy but SUCLA2 deletion induces a metabolic weakness. The study showed that thymoquinone selectively killed SUCLA2-deficient prostate cancer cells in vitro and in vivo. The findings highlight a vulnerability of advanced prostate cancer cells that can be targeted by drugs. (2020-10-07)

Fostamatinib in chronic immune thrombocytopenia: No comparison -- added benefit not proven
Fostamatinib in chronic immune thrombocytopenia: no comparison -- added benefit not proven The manufacturer conducted no direct or indirect comparison of its drug with an appropriate comparator therapy (eltrombopag or romiplostim). (2020-10-06)

Page 2 of 25 | 1000 Results
   First   Previous   Next      Last   
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.